51 related articles for article (PubMed ID: 33652352)
1. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
[TBL] [Abstract][Full Text] [Related]
2. Discovery, Optimization, and Evaluation of Novel Pyridin-2(1
Xu Z; Peng X; Zhang R; Ji Y; You M; Wang D; Shen Y; Zheng M; Li C; Ai J; Liu H
J Med Chem; 2024 Jan; 67(2):1168-1183. PubMed ID: 38227770
[TBL] [Abstract][Full Text] [Related]
3. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
Kiely-Collins H; Winter GE; Bernardes GJL
Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response.
Zhu X; Wang X; Yan W; Yang H; Xiang Y; Lv F; Shi Y; Li HY; Lan L
NAR Cancer; 2021 Mar; 3(1):zcab010. PubMed ID: 33778494
[TBL] [Abstract][Full Text] [Related]
5. Classification models for predicting the bioactivity of pan-TRK inhibitors and SAR analysis.
Zhao X; Kong Y; Ji Y; Xin X; Chen L; Chen G; Yu C
Mol Divers; 2023 Nov; ():. PubMed ID: 37910346
[TBL] [Abstract][Full Text] [Related]
6. The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells.
Zhou YQ; Bao TS; Xie JX; Yao LL; Yu ST; Li Q; Huang PQ; Zhou WZ; Wang YY; Chen SY; Wang XQ; Zhang XL; Jiang SH; Yi SQ; Zhang ZG; Ma MZ; Hu LP; Xu J; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1049-1067. PubMed ID: 37012514
[TBL] [Abstract][Full Text] [Related]
7. Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells.
Yang C; Guo X; Li J; Han J; Jia L; Wen HL; Sun C; Wang X; Zhang B; Li J; Chi Y; An T; Wang Y; Wang Z; Li H; Li L
Front Microbiol; 2022; 13():850444. PubMed ID: 35359739
[TBL] [Abstract][Full Text] [Related]
8. A New Class of Bi- and Trifunctional Sugar Oximes as Antidotes against Organophosphorus Poisoning.
Da Silva O; Probst N; Landry C; Hanak AS; Warnault P; Coisne C; Calas AG; Gosselet F; Courageux C; Gastellier AJ; Trancart M; Baati R; Dehouck MP; Jean L; Nachon F; Renard PY; Dias J
J Med Chem; 2022 Mar; 65(6):4649-4666. PubMed ID: 35255209
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract][Full Text] [Related]
10. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure, Hirshfeld surface analysis and DFT study of
Al Ati G; Chkirate K; Mague JT; Abad N; Achour R; Essassi EM
Acta Crystallogr E Crystallogr Commun; 2021 Jun; 77(Pt 6):638-642. PubMed ID: 34164143
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
14. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
15. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
17. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
